Cyclo Therapeutics, Inc. (CYTH)
USD 0.72
(0.0%)
USD 0.72
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -20.05 Million USD | -31.27% |
| 2022 | -15.27 Million USD | -6.81% |
| 2021 | -14.3 Million USD | -60.32% |
| 2020 | -8.92 Million USD | -16.27% |
| 2019 | -7.67 Million USD | -80.36% |
| 2018 | -4.25 Million USD | -11.01% |
| 2017 | -3.83 Million USD | 9.25% |
| 2016 | -4.22 Million USD | -65.55% |
| 2015 | -2.55 Million USD | -330.48% |
| 2014 | -592.68 Thousand USD | -389.24% |
| 2013 | 204.9 Thousand USD | 176.15% |
| 2012 | 74.2 Thousand USD | 175.9% |
| 2011 | -97.76 Thousand USD | -160.52% |
| 2010 | -37.52 Thousand USD | 80.57% |
| 2009 | -193.12 Thousand USD | 53.26% |
| 2008 | -413.23 Thousand USD | -163.23% |
| 2007 | 653.55 Thousand USD | 741.84% |
| 2006 | -101.82 Thousand USD | 40.96% |
| 2005 | -172.46 Thousand USD | 69.29% |
| 2004 | -561.49 Thousand USD | -290.35% |
| 2003 | 294.97 Thousand USD | 78.15% |
| 2002 | 165.58 Thousand USD | 245.4% |
| 2001 | -113.88 Thousand USD | 77.71% |
| 2000 | -510.82 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -5.98 Million USD | -37.72% |
| 2024 Q1 | -4.34 Million USD | 23.03% |
| 2023 FY | -20.05 Million USD | -31.27% |
| 2023 Q1 | -5 Million USD | -4.07% |
| 2023 Q2 | -4.63 Million USD | 7.4% |
| 2023 Q4 | -5.64 Million USD | -18.26% |
| 2023 Q3 | -4.77 Million USD | -2.91% |
| 2022 Q1 | 162.86 Billion USD | 5832503.84% |
| 2022 FY | -15.27 Million USD | -6.81% |
| 2022 Q4 | -4.81 Million USD | -13.33% |
| 2022 Q3 | -4.24 Million USD | -23.12% |
| 2022 Q2 | -3.44 Million USD | -100.0% |
| 2021 Q3 | -3.86 Million USD | -7.31% |
| 2021 Q2 | -3.59 Million USD | 10.88% |
| 2021 FY | -14.3 Million USD | -60.32% |
| 2021 Q1 | -4.03 Million USD | -50.64% |
| 2021 Q4 | -2.79 Million USD | 27.66% |
| 2020 Q2 | -2.19 Million USD | 16.77% |
| 2020 FY | -8.92 Million USD | -16.27% |
| 2020 Q3 | -1.43 Million USD | 34.52% |
| 2020 Q4 | -2.67 Million USD | -86.65% |
| 2020 Q1 | -2.63 Million USD | 0.04% |
| 2019 Q1 | -1.9 Million USD | -39.44% |
| 2019 Q3 | -1.62 Million USD | -18.81% |
| 2019 Q4 | -2.63 Million USD | -62.12% |
| 2019 FY | -7.67 Million USD | -80.36% |
| 2019 Q2 | -1.36 Million USD | 28.16% |
| 2018 Q1 | -812.94 Thousand USD | 41.26% |
| 2018 Q3 | -787.3 Thousand USD | 38.93% |
| 2018 Q4 | -1.36 Million USD | -73.45% |
| 2018 FY | -4.25 Million USD | -11.01% |
| 2018 Q2 | -1.28 Million USD | -58.59% |
| 2017 Q2 | -827.77 Thousand USD | 16.17% |
| 2017 Q1 | -987.47 Thousand USD | -18.69% |
| 2017 Q4 | -1.38 Million USD | -118.39% |
| 2017 FY | -3.83 Million USD | 9.25% |
| 2017 Q3 | -633.74 Thousand USD | 23.44% |
| 2016 Q4 | -831.97 Thousand USD | 48.48% |
| 2016 Q1 | -705.77 Thousand USD | 33.13% |
| 2016 FY | -4.22 Million USD | -65.55% |
| 2016 Q2 | -1.07 Million USD | -51.77% |
| 2016 Q3 | -1.61 Million USD | -50.76% |
| 2015 Q2 | -360.18 Thousand USD | 7.23% |
| 2015 Q1 | -388.25 Thousand USD | -22.37% |
| 2015 Q4 | -1.05 Million USD | -41.18% |
| 2015 FY | -2.55 Million USD | -330.48% |
| 2015 Q3 | -747.55 Thousand USD | -107.55% |
| 2014 FY | -592.68 Thousand USD | -389.24% |
| 2014 Q1 | 96.92 Thousand USD | 214.89% |
| 2014 Q4 | -317.27 Thousand USD | -43.62% |
| 2014 Q3 | -220.9 Thousand USD | -45.88% |
| 2014 Q2 | -151.43 Thousand USD | -256.24% |
| 2013 Q3 | -94.51 Thousand USD | -135.84% |
| 2013 Q4 | -84.36 Thousand USD | 10.74% |
| 2013 Q2 | 263.7 Thousand USD | 119.61% |
| 2013 Q1 | 120.07 Thousand USD | -8.06% |
| 2013 FY | 204.9 Thousand USD | 176.15% |
| 2012 Q3 | -45.73 Thousand USD | 18.95% |
| 2012 Q4 | 130.6 Thousand USD | 385.54% |
| 2012 Q2 | -56.43 Thousand USD | -223.29% |
| 2012 Q1 | 45.77 Thousand USD | 132.59% |
| 2012 FY | 74.2 Thousand USD | 175.9% |
| 2011 FY | -97.76 Thousand USD | -160.52% |
| 2011 Q1 | -10.22 Thousand USD | -115.65% |
| 2011 Q2 | 35.37 Thousand USD | 446.13% |
| 2011 Q3 | 17.54 Thousand USD | -50.4% |
| 2011 Q4 | -140.47 Thousand USD | -900.54% |
| 2010 Q3 | -37.03 Thousand USD | -244.0% |
| 2010 Q1 | -91.52 Thousand USD | 43.59% |
| 2010 FY | -37.52 Thousand USD | 80.57% |
| 2010 Q2 | 25.71 Thousand USD | 128.1% |
| 2010 Q4 | 65.3 Thousand USD | 276.36% |
| 2009 Q3 | 32.73 Thousand USD | 407.4% |
| 2009 FY | -193.12 Thousand USD | 53.26% |
| 2009 Q1 | -52.95 Thousand USD | 84.36% |
| 2009 Q2 | -10.64 Thousand USD | 79.89% |
| 2009 Q4 | -162.25 Thousand USD | -595.67% |
| 2008 Q1 | -67.28 Thousand USD | -113.59% |
| 2008 Q4 | -338.62 Thousand USD | -21357.12% |
| 2008 Q3 | 1593.00 USD | 117.88% |
| 2008 Q2 | -8911.00 USD | 86.76% |
| 2008 FY | -413.23 Thousand USD | -163.23% |
| 2007 Q3 | 70.03 Thousand USD | -17.71% |
| 2007 FY | 653.55 Thousand USD | 741.84% |
| 2007 Q4 | 495.09 Thousand USD | 606.95% |
| 2007 Q2 | 85.1 Thousand USD | 2468.94% |
| 2007 Q1 | 3313.00 USD | 904.13% |
| 2006 Q2 | -19.11 Thousand USD | 4.65% |
| 2006 FY | -101.82 Thousand USD | 40.96% |
| 2006 Q4 | -412.00 USD | 99.34% |
| 2006 Q3 | -62.25 Thousand USD | -225.74% |
| 2006 Q1 | -20.04 Thousand USD | 93.73% |
| 2005 FY | -172.46 Thousand USD | 69.29% |
| 2005 Q1 | 200.47 Thousand USD | 181.57% |
| 2005 Q2 | 21.51 Thousand USD | -89.27% |
| 2005 Q3 | -74.69 Thousand USD | -447.13% |
| 2005 Q4 | -319.76 Thousand USD | -328.08% |
| 2004 Q4 | -245.77 Thousand USD | -2275.73% |
| 2004 FY | -561.49 Thousand USD | -290.35% |
| 2004 Q3 | 11.29 Thousand USD | 103.77% |
| 2004 Q2 | -299.65 Thousand USD | -4058.42% |
| 2004 Q1 | -7206.00 USD | -102.79% |
| 2003 Q1 | -11.41 Thousand USD | 60.89% |
| 2003 FY | 294.97 Thousand USD | 78.15% |
| 2003 Q4 | 258.13 Thousand USD | 833.85% |
| 2003 Q3 | 27.64 Thousand USD | 34.08% |
| 2003 Q2 | 20.61 Thousand USD | 280.62% |
| 2002 Q4 | -29.18 Thousand USD | -132.98% |
| 2002 Q2 | 52.67 Thousand USD | -1.74% |
| 2002 Q1 | 53.6 Thousand USD | 260.51% |
| 2002 Q3 | 88.48 Thousand USD | 67.99% |
| 2002 FY | 165.58 Thousand USD | 245.4% |
| 2001 Q2 | 86.00 USD | 100.31% |
| 2001 Q1 | -27.65 Thousand USD | 91.0% |
| 2001 FY | -113.88 Thousand USD | 77.71% |
| 2001 Q4 | -33.39 Thousand USD | 36.88% |
| 2001 Q3 | -52.91 Thousand USD | -61626.74% |
| 2000 Q3 | -67.92 Thousand USD | 0.0% |
| 2000 FY | -510.82 Thousand USD | 0.0% |
| 2000 Q4 | -307.32 Thousand USD | -352.46% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 141.652% |
| Embecta Corp. | 70.4 Million USD | 128.49% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | 206.807% |
| Dynavax Technologies Corporation | -6.38 Million USD | -213.935% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 90.415% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 147.807% |
| PainReform Ltd. | -9.34 Million USD | -114.654% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | -154.858% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -345.12% |
| SCYNEXIS, Inc. | 67.04 Million USD | 129.918% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | -547.316% |
| Cosmos Health Inc. | -18.54 Million USD | -8.168% |
| Journey Medical Corporation | -3.85 Million USD | -420.563% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -345.12% |
| Safety Shot Inc | -15.08 Million USD | -32.979% |
| Alpha Teknova, Inc. | -36.78 Million USD | 45.467% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 85.64% |
| Bright Green Corporation | -13.12 Million USD | -52.787% |
| Procaps Group, S.A. | 42.54 Million USD | 147.149% |
| Theratechnologies Inc. | -23.95 Million USD | 16.278% |
| Harrow Health, Inc. | -24.41 Million USD | 17.835% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | -314.836% |
| Biofrontera Inc. | -20.13 Million USD | 0.366% |
| DURECT Corporation | -27.62 Million USD | 27.392% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 1624.111% |
| Cronos Group Inc. | -73.96 Million USD | 72.882% |
| OptiNose, Inc. | -35.48 Million USD | 43.473% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 97.999% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 52.47% |
| RedHill Biopharma Ltd. | 23.91 Million USD | 183.866% |
| Organogenesis Holdings Inc. | 4.94 Million USD | 505.608% |
| Guardion Health Sciences, Inc. | 158.03 Thousand USD | 12791.844% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | -219.418% |
| Radius Health, Inc. | -25.79 Million USD | 22.231% |
| Universe Pharmaceuticals INC | -6.16 Million USD | -225.444% |
| ProPhase Labs, Inc. | -16.78 Million USD | -19.517% |
| Phibro Animal Health Corporation | 2.41 Million USD | 930.186% |
| Procaps Group S.A. | 42.54 Million USD | 147.149% |
| Alvotech | -551.73 Million USD | 96.365% |
| TherapeuticsMD, Inc. | -10.27 Million USD | -95.148% |
| Viatris Inc. | 54.7 Million USD | 136.668% |
| Rockwell Medical, Inc. | -8.43 Million USD | -137.674% |
| Aytu BioPharma, Inc. | -15.84 Million USD | -26.592% |
| SIGA Technologies, Inc. | 68.06 Million USD | 129.466% |
| Tilray Brands, Inc. | -244.98 Million USD | 91.813% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | 266.963% |
| Shineco, Inc. | -22.44 Million USD | 10.654% |
| PetIQ, Inc. | 2.13 Million USD | 1041.215% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | -366.25% |
| Incannex Healthcare Limited | -18.45 Million USD | -8.659% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 108.033% |
| Alimera Sciences, Inc. | -20.13 Million USD | 0.371% |
| Silver Spike Investment Corp. | 7.34 Million USD | 373.256% |
| Assertio Holdings, Inc. | -331.94 Million USD | 93.958% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | -204.234% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | -145.704% |
| Clever Leaves Holdings Inc. | -17.89 Million USD | -12.058% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 87.486% |
| Hempacco Co., Inc. | -13.12 Million USD | -52.805% |
| Talphera, Inc. | -18.39 Million USD | -9.025% |
| Alvotech | -551.73 Million USD | 96.365% |
| Eagle Pharmaceuticals, Inc. | 35.64 Million USD | 156.274% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 106.14% |
| Currenc Group, Inc. | -15.3 Million USD | -31.037% |
| Kamada Ltd. | 8.28 Million USD | 342.121% |
| Indivior PLC | 2 Million USD | 1102.865% |
| Evoke Pharma, Inc. | -7.79 Million USD | -157.399% |
| Flora Growth Corp. | -57.03 Million USD | 64.834% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -0.0% |
| Evolus, Inc. | -61.68 Million USD | 67.484% |
| HUTCHMED (China) Limited | 100.78 Million USD | 119.902% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 114.582% |
| Akanda Corp. | -32.27 Million USD | 37.855% |